The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.
 
Chetan Vakkalagadda
No Relationships to Disclose
 
Sabeeha Mukit
No Relationships to Disclose
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Boston Scientific; BTG; Exelixis; Incyte; QED Therapeutics
Speakers' Bureau - Boston Scientific; Exelixis; Genentech/Roche
Research Funding - Bristol-Myers Squibb (Inst)
 
Mary Frances Mulcahy
Consulting or Advisory Role - Boston Scientific
Research Funding - BTG
 
Al Bowen Benson
Consulting or Advisory Role - Abbvie; Apexigen; Array BioPharma; Artemida Pharma; Boston Scientific; Bristol-Myers Squibb; HalioDx; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Natera; Pfizer; Samsung Bioepis; Therabionic; Xencor
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITM Solucin (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)
 
Navdeep Chandel
No Relationships to Disclose
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics